



ESC Declaration of Interest Report
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in Guidelines development to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs are assessed prior to work commencing, and the ESC may decide to exclude any expert from a Guidelines activity based on the exclusion criteria as defined in the *ESC Declaration and Management of Conflict of Interest Policy, Annex 3*, as approved in July 2020.

The current policy and its annexes are available on the ESC website at www.escardio.org/DOI

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Back Maria	<p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>- Sanofi Aventis : One speaker fee on "What is the future on cardiac rehabilitation?". 500 Euro payment</p>
	<p>2020</p> <p>Nothing to be declared</p>
Benetos Athanase	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>- Fukuda Denshi : Arterial stiffness assessment</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <p>- Fukuda Denshi : Arterial Stiffness</p> <p>- Menarini : Cardiogeriatrics</p>
	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <p>- Novartis : Dementia</p>
Biffi Alessandro	<p>2019</p> <p>Nothing to be declared</p>
	<p>2020</p> <p>Nothing to be declared</p>

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Boavida Jose Manuel	<p>2019</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Abbott : diabetes - Astra Zeneca : diabetes - Merck Sharp & Dohme : diabetes - Novo-Nordisk : diabetes <hr style="border-top: 1px dashed black;"/> <p>2020</p> <p>Nothing to be declared</p>
Capodanno Davide	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antithrombotic therapy - Bayer : Antithrombotic therapy - Boehringer-Ingelheim : Antithrombotic therapy - Daiichi Sankyo : Antithrombotic therapy - Sanofi Aventis : Antithrombotic therapy - Abbott : PCI - Biosensors : PCI - Boston Scientific : PCI - Amgen : Pharmacology

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Capodanno Davide	<p>2019</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. - Supplier - Minor shareholder of CERC, an European CRO provider</p>
	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Antithrombotic therapy - Bayer : Antithrombotic therapy - Boehringer-Ingelheim : Antithrombotic therapy - Daiichi Sankyo : Antithrombotic therapy - Medtronic : Coronary stents - Biotronik : Coronary stents - Menarini : Drugs - Amgen : Pharmacology</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. - Supplier - Minor shareholder of CERC (<5,000 Euros/year), a European CRO provider.</p>

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Carballo David	<p>2019</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Bayer AG : Bayer contributed towards registration fees, travel and hotel expenses for participation at the ESC Annual Conference Paris 2019</p>
	<p>2020</p> <p>Nothing to be declared</p>
Cosyns Bernard	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Medtronic : Prosthetic valves - Abbott : Prosthetic valves - ischemic heart disease</p> <p>Receipt of royalties for intellectual property. - Oxford University Press : Echocardiography</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - HeartFlow : Coronary disease</p>
	<p>2020</p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property. - Oxford University Press : Echocardiography</p>
Crawford Carolyn	<p>2019</p> <p>Nothing to be declared</p>

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Crawford Carolyn	2020 Other Positions of Influence Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Member of ESC Patients' Forum
	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Amgen : Advisory Board fees / Lipids - Menarini Hellas : Training Reps fees / Angina, Coronary Artery Disease
Davos Constantinos	2020 Nothing to be declared
	2019 Nothing to be declared
Desormais Ileana	2020 Nothing to be declared
	2019 Nothing to be declared
Di Angelantonio Emanuele	2020 Nothing to be declared
	2019 Nothing to be declared
Franco Duran Oscar	2020 Nothing to be declared
	2019 Nothing to be declared

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulation - Pfizer : Anticoagulation - Bristol Myers Squibb : Anticoagulation - Bayer AS : Anticoagulation - Merck Sharp & Dohme : Glucose lowering drugs - Sanofi Aventis : Lipid lowering treatment <hr style="border-top: 1px dashed black;"/> <p>2020</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Anticoagulation - Sanofi Aventis : Lipidlowering <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation - Pfizer : Anticoagulation - Novartis : Heart failure
Hobbs Richard	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : AF, aspirin - Boehringer-Ingelheim : Diabetes

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Hobbs Richard	2019 - Novo-Nordisk : Diabetes - Novartis : Heart failure
	2020 Financial Declaration - Bayer : AF, aspirin - Boehringer-Ingelheim : Diabetes - Novartis : Heart failure
Hollander Monika	2019 Nothing to be declared
	2020 Nothing to be declared
Jankowska Ewa Anita	2019 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer : anticoagulants - Astra Zeneca : antiplatelets - Boehringer-Ingelheim : diabetes and CVD - Novartis : Entresto - Abbott : FMR in heart failure - Cardiac Dimensions : heart failure devices - Servier : heart failure, ivabradine - Gedeon Richter : hiperlip;idemia - Fresenius Nutrition : iv iron - Vifor International : IV iron

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p>2019</p> <ul style="list-style-type: none"> - Berlin Chemie AG : lecanidipine, torasemide <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Vifor International : iv iron <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> - University of Zurich : heart failure - National Centre for Science (Poland) : iron metabolism, heart failure
	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : anticoagulants, vericiguat - Astra Zeneca : antiplatelets, dapagliflozine - Boehringer-Ingelheim : diabetes and CVD, empagliflozine - Sanofi Aventis : Fabry disease - Abbott : FMR in heart failure - Cardiac Dimensions : heart failure devices - Vifor International : IV iron - Respicardia : phrenic nerve stimulation in CSA - Novartis : sacubitril/valsartan <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Vifor International : iv iron

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<p>2020</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Payment from University of Zurich for lectures during the Postgraduate HF Course. Payment from NCBIR (Polish public entity) for research activities in the area of telemedicine in heart failure and non coding RNA</p>
Koskinas Konstantinos	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Amgen : Cardiovascular</p>
	<p>2020</p> <p>Financial Declaration</p> <p>- Amgen : Cardiology - Daiichi Sankyo : Cardiology</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Cardiology</p>
Mach Francois	<p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Lipid - Amgen : Lipids - Sanofi Aventis : Lipids</p>

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Mach Francois	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Heart Failure - Novartis : Heart Failure/Lipid - Daiichi Sankyo : Lipids - Sanofi Aventis : Lipids - Amgen Inc : Lipids - MSD : Lipids
Michal Matthias	<p>2019</p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Kohlhammer publishing house : Book <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - German Society of Cardiology (DGK) German College of Psychosomatic Medicine (DKPM) <hr style="border-top: 1px dashed black;"/> <p>2020</p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Kohlhammer Verlag : Book, Psychotherapy

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Michal Matthias	<p>2020</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Deutsche Gesellschaft für Kardiologie</p>
Sacco Simona	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Cardiovascular - left atrial appendage occlusion - Medscape : Migraine - Eli Lilly : Migraine - monoclonal antibodies - Novartis : Migraine - monoclonal antibodies - Teva Pharmaceutical Industries : Migraine - monoclonal antibodies - Allergan : Migraine, botulinum toxin <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Cardiovascular - anticoagulants - Pfizer : Cardiovascular - anticoagulants - Bayer Healthcare : Cardiovascular - anticoagulants - Bristol Myers Squibb : Cardiovascular - anticoagulants - Starmed : Cardiovascular - loop recorder - Medtronic : Cardiovascular - PFO closure - Eli Lilly : Migraine - Novartis : Migraine - Teva Pharmaceutical Industries : Migraine

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Sacco Simona	2019 - Allergan : Migraine
	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Antiplatelets - Abbott : Cardiovascular - left atrial appendage occlusion - Medscape : Migraine - Eli Lilly : Migraine - monoclonal antibodies - Novartis : Migraine - monoclonal antibodies - Teva Pharmaceutical Industries : Migraine - monoclonal antibodies - Allergan : Migraine, botulinum toxin Travel and meeting support from healthcare industry, independent of the above activities. - Daiichi Sankyo : Cardiovascular - anticoagulants - Pfizer : Cardiovascular - anticoagulants - Bayer Healthcare : Cardiovascular - anticoagulants - Bristol Myers Squibb : Cardiovascular - anticoagulants - Starmed : Cardiovascular - loop recorder - Medtronic : Cardiovascular - PFO closure - Eli Lilly : Migraine - Novartis : Migraine - Teva Pharmaceutical Industries : Migraine - Allergan : Migraine

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Sattar Naveed	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes - Eli Lilly : diabetes - Pfizer : diabetes - Novo-Nordisk : diabetes - Astrazeneca : diabetes - Amgen : lipids - Sanofi Aventis : lipids and diabetes <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes - Eli Lilly : diabetes - Sanofi Aventis : diabetes - Amgen : lipids <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes <hr style="border-top: 1px dashed black;"/> <p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes - Eli Lilly : diabetes

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Sattar Naveed	<p>2020</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : diabetes - Novo-Nordisk : diabetes - Novartis : lipids - Sanofi Aventis : lipids and diabetes <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : diabetes - Boehringer-Ingelheim : diabetes - Eli Lilly : diabetes - Pfizer : diabetes - Sanofi Aventis : diabetes - Novo-Nordisk : diabetes - Amgen : lipids <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes
Smulders Yvo	<p>2019</p> <p style="text-align: center;">Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p>2020</p> <p style="text-align: center;">Nothing to be declared</p>
Tokgozoglulale	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : antiplatelet,lipid

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry	
Tokgozoglulale	2019	<ul style="list-style-type: none"> - Novo-Nordisk : diabetes - Abbott : dyslipidemia - Recordati International : dyslipidemia - Mylan : dyslipidemia - Servier : hypertension - Amgen : lipid - Daiichi Sankyo : Lipids - MSD : Lipids - Pfizer : lipids, cardiomyopathy - Actelion : pulmonary hypertension - Bayer Healthcare : stroke prevention
	2020	<p>Financial Declaration</p> <ul style="list-style-type: none"> - Pfizer : Anticoagulation - Novo-Nordisk : Diabetes - Servier : Hypertension - Abbott : Lipids - Amgen : Lipids - Novartis : Lipids - Sanofi Aventis : Lipids - Recordati International : Lipids - MSD : Lipids - Daiichi-Sankyo : Lipids - Mylan : Lipids

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry	
Tokgozoglulale	2020	<ul style="list-style-type: none"> - Abdi-Ibrahim : Lipids - Actelion/Jansen : Pulmonary hypertension - Bayer : Pulmonary hypertension, heart failure
Tonstad Serena	2019	<p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes type 2 - lifestyle - Merck Sharp & Dohme : Diabetes type 2 - lifestyle - Novo-Nordisk : Diabetes type 2, obesity - Amgen : Hyperlipidemia - medication, lifestyle - Sanofi Aventis : Hyperlipidemia, Diabetes type 2 - lifestyle - Navamedic : Obesity - Pfizer : Smoking cessation
	2020	<p>Financial Declaration</p> <ul style="list-style-type: none"> - Bayer : Cardiovascular disease - Boehringer-Ingelheim : Diabetes and lifestyle - Merck Sharp & Dohme : Diabetes type 2 - lifestyle - Sanofi Aventis : Hyperlipidemia, Diabetes type 2 - lifestyle - Novartis : Lipids

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Tsioufis Costas	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiology - Bayer : Cardiology - Boehringer-Ingelheim : Cardiology - Medtronic : Cardiology - Novartis : Cardiology - Pfizer : Cardiology - Servier : Cardiology - St Jude Medical : Cardiology - Sanofi Aventis : Cardiology - Chiesi Pharma : Cardiology - Recordati International : Cardiology - Vianex : Cardiology - Winmedica : Cardiology - ELPEN : Cardiology <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : Cardiology - St Jude Medical : Cardiology

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Tsioufis Costas	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiology - Bayer : Cardiology - Boehringer-Ingelheim : Cardiology - Medtronic : Cardiology - Novartis : Cardiology - Pfizer : Cardiology - Servier : Cardiology - St Jude Medical : Cardiology - Sanofi Aventis : Cardiology - Chiesi Pharma : Cardiology - Recordati International : Cardiology - Vianex : Cardiology - Winmedica : Cardiology - ELPEN : Cardiology <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : Cardiology - St Jude Medical : Cardiology

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Van Dis Ineke	<p>2019</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology. - European Heart Network, Brussel</p>
	<p>2020</p> <p>Nothing to be declared</p>
Van Gelder Isabelle C	<p>2019</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - BMS : Atrial fibrillation</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - BMS : Atrial fibrillation</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Daiichi Sankyo : Atrial fibrillation - Medtronic : Atrial fibrillation</p>
	<p>2020</p> <p>Financial Declaration - Daiichi Sankyo : Atrial Fibrillation - Medtronic : Atrial Fibrillation</p>
Visseren Frank	<p>2019</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Amgen : Familial Dysbetalipoproteinemia</p>

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Visseren Frank	<p>2020</p> <p>Financial Declaration</p> <ul style="list-style-type: none"> - Amgen : Familial Dysbetalipoproteinemia
Wanner Christoph	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - GSK : Anemia - Akebia : Anemia - BMS : Apixaban - Reata : Bardoxolone - ChiesiPharma : Cystinosis, Fabry disease - Astra Zeneca : Dapagliflozin, Diabetes - Gilead : diabetic kidney disease - FMC : Dialysis - Boehringer-Ingelheim : Empagliflozin, Diabetes - Lilly : empagliflozin, diabetes - Daiischi-Sankyo : Enoxaparin - MSD : Ertugliflozin, Diabetes - Sanofi-Genzyme : Fabry - Amicus : Fabry disease - Shire/Takeda : Fabry disease - Bayer : Finerenone, Cardio-Renal - Novartis : heart failure, entresto - Astellas : Immunology

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Wanner Christoph	<p>2019</p> <ul style="list-style-type: none"> - Synlab : laboratory tests and medicine - Tricida : metabolic acidosis - Vifor International : Metabolic bone disease, anemia - Nestle : Nutrition <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes - Idorsia : Fabry disease - Sanofi-Genzyme : Fabry disease
	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - GSK : Anemia - ChiesiPharma : Cystinosis, Fabry disease - Astra Zeneca : Dapagliflozin, Diabetes - Gilead : diabetic kidney disease - FMC : Dialysis - Boehringer-Ingelheim : Empagliflozin, Diabetes - Lilly : empagliflozin, diabetes - MSD : Ertugliflozin, Diabetes - Takeda Pharmaceuticals : Fabry disease - Idorsia : Fabry disease - Sanofi-Genzyme : Fabry disease - Bayer : Finerenone, Cardio-Renal

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Wanner Christoph	<p>2020</p> <ul style="list-style-type: none"> - Astellas : Immunology - Tricida : metabolic acidosis - Vifor International : Metabolic bone disease, anemia - Nestle : Nutrition <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes - Sanofi-Genzyme : Fabry disease
Williams Bryan	<p>2019</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Hypertension - Daiichi Sankyo : Hypertension - Novartis : Hypertension - Servier : Hypertension - Vascular Dynamics Inc, USA : Hypertension - device based therapy - Pfizer : Hypertension and cardiovascular risk management <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Vascular Dynamics Inc USA : Mobius HD device for baroreceptor amplification in resistant hypertension <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - I am an academic funded by the University and also undertake medical practice in the NHS as part of my responsibilities but my employer is the University, not the NHS.

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Williams Bryan	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Hypertension - Daiichi Sankyo : Hypertension - Novartis : Hypertension - Servier : Hypertension - Vascular Dynamics Inc, USA : Hypertension - device based therapy - Pfizer : Hypertension and cardiovascular risk management <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - OMRON Healthcare : Blood pressure measurement <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - I am an academic funded by the University and also undertake medical practice in the NHS as part of my responsibilities but my employer is the University, not the NHS. <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - Trustee of the Charity Blood Pressure UK - a patient support Charity - Pro-Bono work

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Aamodt Anne Hege	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Allergan : headache - Roche Diagnostics : headache <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : CRAO - Medtronic : Stroke
Abdelhamid Magdy	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer AG : Advisory board fees - Astra Zeneca : speaker fees - Boehringer-Ingelheim : speaker fees - Novartis : speaker fees
Abdessalem Salem	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astrazeneca : ACS - Servier : HTN
Abela Mark	<p>2020</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Antithrombotic therapies - Bristol Myers Squibb : Antithrombotic therapies - Astrazeneca : Diabetes <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bayer Healthcare : Peripheral Artery Disease
Alakbarov Elman	<p>2020</p> <p>Nothing to be declared</p>
Alami Mohamed	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anti diabetics drugs and Anticoagulants - Astra Zeneca : Dyslipidemia - Pfizer : Dyslipidemia and anticoagulants - Novartis : Hypertension - Sanofi Aventis : Hypertension - Technimed : Hypertension - Merck : Hypertension - Afric Phar : Hypertension - Sothema : Hypertension - Abbott : LIPIDS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Albus Christian	<p>2020</p> <p>Nothing to be declared</p>
Andersen Karl	<p>2020</p> <p>Nothing to be declared</p>
Arnaout M Samir	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : antiplatelet agents - Abbott Laboratories : Centrally acting antihypertension drugs - Novartis : heart failure - Boehringer-Ingelheim : hypertension
Asteggiano Riccardo	<p>2020</p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979
Back Magnus	<p>2020</p> <p>Nothing to be declared</p>
Bani Marjeh Mohammed Yassin	<p>2020</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Banu Cristiana	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Atrial Fibrillation - Pfizer : Atrial Fibrillation - Bayer : Atrial fibrollation - Boehringer-Ingelheim : Diabetes
Barilla Francesco	<p>2020</p> <p>Nothing to be declared</p>
Belenkov Yury	<p>2020</p> <p>Nothing to be declared</p>
Bertelli Luca	<p>2020</p> <p>Nothing to be declared</p>
Borger Michael A	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Cryolife : aortic surgery - Abbott : heart valve therapy - Edwards Lifesciences : heart valve therapy - Medtronic : heart valve therapy
Bosevski Marijan	<p>2020</p> <p>Nothing to be declared</p>

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Boskovic Aneta	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Boehringer-Ingelheim : Atrial fibrillation</p>
Bovin Ann	<p>2020</p> <p>Nothing to be declared</p>
Brotos Carlos	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer AG : advisory board ARRIVE trial</p>
Celutkiene Jelena	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Pfizer : anticoagulation - Amgen : heart failure - Boehringer-Ingelheim : heart failure - Novartis : heart failure - Bayer Healthcare : heart failure - Astrazeneca : heart failure</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Roche Diagnostics : heart failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Cifkova Renata	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen Czech republic : speaker fee - Herbacos Recordati Czech Republic : speaker fee - Krka Czech Republic : speaker fee
Cikes Maja	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulation - Pfizer : Anticoagulation, amyloidosis - Astra Zeneca : coronary heart disease - Astra Zeneca : Heart Failure - Boehringer-Ingelheim : Heart failure - Novartis : Heart failure - Orion : Heart failure - Teva Pharmaceutical Industries : Heart failure <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : heart failure - CorVia : Heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott : Heart failure

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Cikes Maja	2020 - Novartis : Heart failure
Cosentino Francesco	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Boehringer-Ingelheim : Cardiovascular Disease - Pfizer : CVD - Merck Sharp & Dohme : CVD and Diabetes - Novo-Nordisk : CVD and Diabetes
Dagres Nikolaos	2020 Nothing to be declared
Dalmau Regina	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Lipids - Sanofi Aventis : Lipids Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Amgen Inc : Lipids
de Backer Tine Leonie Marie	2020 Financial Declaration Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Servier : Supports logistically (press of the paper invitations, auditorium and catering) the yearly Belgian Hypertension Committee (BHC) educational symposium for GPs; Servier has no participation in the scientific program/topics itself

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
de Backer Tine Leonie Marie	<p>2020</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - I am active in the Belgian center for Pharmacotherapeutic information (BCFI) I am member of the University Hospital Pharmaceutical Committee This contains no financial or other personal advantages</p>
De Backer Guy	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Daiichi Sankyo : advisory board</p>
De Bacquer Dirk	<p>2020</p> <p>Nothing to be declared</p>
De Sutter Johan	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : heart failure - Actelion : pulmonary hypertension</p>
Delgado Victoria	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Medtronic : aortic stenosis (speaker fee in 2019 <1000 euro) - MSD : diabetes - speaker fee (800 euro) - GE Healthcare : echocardiography (<2000 euro) - Novartis : heart failure (speaker fee 800 euro)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>2020</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitral valve disease (<2000 euro) - Edwards Lifesciences : valvular heart disease (<2000 euro) <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - GE Healthcare : echocardiography - Edwards Lifesciences : tricuspid valve disease <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member of AHA, associate editor of Circulation and JASE
Den Ruijter Hester	<p>2020</p> <p>Nothing to be declared</p>
Dendale Paul	<p>2020</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott : drugs - Astra Zeneca : drugs - Boehringer-Ingelheim : drugs - Novartis : drugs - Sanofi Aventis : drugs - Vifor International : drugs - Bristol Myers Squibb : drugs - GE Healthcare : echo - Biosense : material - Medtronic : pm

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Dendale Paul	2020 - Biotronik : PM
Dilic Mirza	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Sanofi Aventis : PCSK9
Drexel Heinz	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - European Society of Cardiology : Cardiology - Novartis : Clinical Lipidology - Austrian Pharmacy Association : Diabetes - Amgen : Lipids - Daiichi Sankyo : Lipids - Medscape : Lipids
Falk Volkmar	2020 Financial Declaration Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Berlin Heart : Advisory - Novartis : Consultancy - Abbott : Educational Grant for HCP's - Edwards Lifesciences : Educational Grant for HCP's - Medtronic : Educational Grant for HCP's

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Falk Volkmar	2020 - Cryolife / Jotec : Educational Grant for HCP's
Fauchier Laurent	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. <ul style="list-style-type: none"> - Bayer : Healthcare - Boehringer-Ingelheim : Healthcare - Medtronic : Healthcare - Novartis : Healthcare - BMS/Pfizer : Healthcare - XO : Healthcare
FERENCE Brian A	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. <ul style="list-style-type: none"> - Sanofi Aventis : Consultant; Advisory Boards; Honoraria - Regeneron : Consultant; Advisory Boards; Honoraria - Amgen : Consultant; Advisory Boards; Research Grant; Honoraria - Merck Sharp & Dohme : Consultant; Advisory Boards; Research Grant; Honoraria - Eli Lilly : Consultant; Honoraria - Novo-Nordisk : Consultant; Honoraria - Krka Pharma : Consultant; Honoraria - Mylan : Consultant; Honoraria - Ionis : Consultant; Honoraria - dalCOR Therapeutics : Consultant; Honoraria

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
FERENCE BRIAN A	<p>2020</p> <ul style="list-style-type: none"> - Medicines Company : Consultant; Honoraria ; Research Grant - Esperion Therapeutics : Consultant; Research Grant; Honoraria - Daiichi Sankyo : Daiichi Sankyo - Novartis : Research Grant, Consultant, Honoraria - Silence Therapeutics : Silence Therapeutics <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Esperion Therapeutics : LDL; ACL inhibition - Mekcrck Sharp & Dohme : LDL; NPC1L1 inhibition - Novartis : Lp(a); Lp(a) inhibition - Amgen : PCSK9 inhibitors; lipids; Lp(a)
FERRIERES JEAN	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : Atherosclerosis - Servier : Atherosclerosis - Sanofi Aventis : Atherosclerosis - MSD : Atherosclerosis - Akcea : Atherosclerosis - Lilly : Diabetes
FERRINI MARC	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Rivaroxaban, Aspirin

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Fisher Miles	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - NAPP : diabetes / canagliflozin - Astra Zeneca : diabetes / dapagliflozin - Eli Lilly : diabetes / dulaglutide - Boehringer-Ingelheim : diabetes / empagliflozin - MSD : diabetes / ertugliflozin - Novo-Nordisk : diabetes / liraglutide / semaglutide - Sanofi Aventis : diabetes / sotagliflozin - Daiichi Sankyo : lipid lowering / bimdepoic acid - Bayer : rivaroxaban - Lexicon : sotagliflozin <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - My honoraria are paid into Miles Fisher Diabetes Advisory Limited
Fliser Danilo	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, FMC, Vifor : Kidney disease

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Fras Zlatko	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes mellitus, anticoagulation - Amgen : lipid treatment - Sanofi Aventis : lipid treatment - Novartis : lipids, heart failure <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Novartis : lipidology - lipoprotein (a)
Gaita Dan	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Advisory Board - Boehringer-Ingelheim : Advisory Board - Novartis : Advisory Board - Novo-Nordisk : Advisory Board - Viartis : Advisory Board - Sanofi Aventis : Honoraria - Societatea Romana de Cardiologie : Honoraria/ Advisory Board <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - Board Member of European Heart Network

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Giampaoli Simona	<p>2020</p> <p>Nothing to be declared</p>
Gielen Stephan	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Advisory Board - personal honoraria 3,285.- € - Boehringer Ingelheim : Advisory board, personal honoraria 1,000,- € - Astra Zeneca : antithrombotic therapy - lecture honoraria - personal honoraria: 1,000.- € - Amgen : PCSK9-inhibitors - lecture honoraria - personal honoraria: 1,200.- € <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Portola Pharmaceuticals : ANNEXA 4 Study - Dr. Härtel - Biotronik : Biosolve Study - Dr. Vlachojannis, Dr. Härtel, Biowomen Studies - Dr. Brockmeier - B. Braun : CONSEQUENT ALL COMERS Registry - CVRx : CVRx-HTN-Registry, Barostim Study - Daiichi Sankyo : ETNA-VTE Registry, ENCOURAGE-AF - Dr. Härtel, SANTORINI - Prof. Gielen - CorVia : REDUCE LAP-HF TRIAL III/ Corvia Medical - Amgen Inc : REPATHA Register - Dr. Härtel - Bayer Vital : XATOA Study, RIVA-PCI-Registry - Dr. Härtel <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Elsevier : Book royalties

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Gielen Stephan	<p>2020</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - German Heart Foundation DGK, ESC, EAPC ALKK</p>
Giga Vojislav	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Krka Pharma : Speaker Fees - Adoc Pharmaceutical Company : Speaker Fees - Servier : Speakers Fees</p>
Gotcheva Nina	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Actelion : PAH</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Teva Pharmaceutical Industries : ESC congress</p>
Graham Ian Maklim	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Sandoz- indirectly through Sciterion : Adherence to preventive advice- educational programme</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Grassos Charalampos	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : HEART FAILURE</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Boehringer-Ingelheim : ANTITHROMBOTICS</p>
Hammoudi Naima	<p>2020</p> <p>Nothing to be declared</p>
Hekkala Anna-Mari	<p>2020</p> <p>Nothing to be declared</p>
Heracleous Hera	<p>2020</p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Pfizer : Panhellenic Seminars of Working Groups 2020</p>
Ibrahimi Pranvera	<p>2020</p> <p>Nothing to be declared</p>
Jennings Catriona Sian	<p>2020</p> <p>Nothing to be declared</p>
Joergensen Torben	<p>2020</p> <p>Nothing to be declared</p>
Kautzky-Willer Alexandra	<p>2020</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Kavousi Maryam	<p>2020</p> <p>Nothing to be declared</p>
Kemps Hareld	<p>2020</p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Abbott : Remote Patient Management</p>
Kiessling Anna	<p>2020</p> <p>Nothing to be declared</p>
Koenig Wolfgang	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : Cardiovascular - Astra Zeneca : Cardiovascular - Novartis : Cardiovascular - Sanofi Aventis : Cardiovascular - Berlin Chemie AG : Cardiovascular - Genentech : Cardiovascular - Kowa : Cardiovascular - Novo-Nordisk : Cardiovascular - The Medicines Company : Cardiovascular - Daiichi-Sankyo : Cardiovascular - Esperion : Cardiovascular - OMEICOS : Cardiovascular

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Koenig Wolfgang	<p>2020</p> <ul style="list-style-type: none"> - Dalcor : Cardiovascular - corvidia : Cardiovascular
Konradi Aleksandra	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : hypertension - Krka Pharma : hypertension - Gedeon Richter : hypertension - Servier : hypertsniion
Kotecha Dipak	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Data Science (Advisory Board) - Amomed : Data Science (Advisory Board) - Protherics Medicines Development : Data Science (Advisory Board) <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bayer : Funding for ESC STEEER-AF trial - Boston Scientific : Funding for ESC STEEER-AF trial - Daiichi Sankyo : Funding for ESC STEEER-AF trial - Boehringer Ingelheim : Funding for ESC STEEER-AF trial - BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial - Amomed : Systematic review

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p>2020</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).
Kownator Serge	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes - Thrombosis - Amgen : lipids - Sanofi Aventis : Lipids - Merck Sharp & Dohme : lipids - Bayer : thrombosis - Pfizer : thrombosis - Philips : vascular Ultrasound
Landmesser Ulf	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer AG : Advisory Board fee - Amgen : Speaker fee - Novartis : Speaker fee

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>2020</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Novartis : Lipid Cardio Study - Bayer AG : Research Grant
Lettino Maddalena	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants - Pfizer : anticoagulants - Bristol Myers Squibb : anticoagulants - Boehringer-Ingelheim : clinical research and drug approval from regulatory agencies - Sanofi Aventis : lipid-lowering drugs
Lewis Basil S	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Vifor International : Heart failure - Kowa : Lipidology - CSL Behring : Lipidology, Secondary prevention <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Kowa : Lipidology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Linhart Ales	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension, coronary heart disease, heart failure - Boehringer-Ingelheim : Atrial fibrillation, diabetes - Sanofi Aventis : Fabry disease - Takeda Pharmaceuticals : Fabry disease
Lochen Maja-Lisa	<p>2020</p> <p>Nothing to be declared</p>
Makrilakis Konstantinos	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes Mellitus - Boehringer-Ingelheim : Diabetes mellitus - Sanofi Aventis : Diabetes mellitus - Lilly : Diabetes mellitus - Merck Sharp & Dohme : Diabetes mellitus - Novo-Nordisk : Diabetes mellitus - Servier : Diabetes mellitus, hypertension, dyslipidemia <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes mellitus

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Mancia Giuseppe	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : HYPERTENSION - Boehringer-Ingelheim : HYPERTENSION - Daiichi Sankyo : HYPERTENSION - Medtronic : HYPERTENSION - Novartis : HYPERTENSION - Servier : HYPERTENSION - Sanofi Aventis : HYPERTENSION - Menarini : HYPERTENSION - Merck Sharp & Dohme : HYPERTENSION - Recordati International : HYPERTENSION - Sandoz : HYPERTENSION <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> - Springer Verlag : HYPERTENSION
Marques-Vidal Pedro	<p>2020</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Received funding from the Swiss national science foundation to conduct a study on sleep and cardiovascular disease (grant 320030E_176280)
Mcevoy John William	<p>2020</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
McGreavy Paul	<p>2020</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - Global Heart Hub ESC Patient Forum
Merkely Bela	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : CRT/ICD - Boehringer Ingelheim : ICD / CRT - Biotronik : ICD/CRT <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Medtronic : cardiac rhythm management - Boston Scientific : CRT
Mintale Iveta	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : investigator - Novo-Nordisk : investigator - Bayer : speaker - Boehringer-Ingelheim : speaker - Novartis : speaker - Servier : speaker

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Mintale Iveta	2020 - Berlin Chemie AG : speaker
Mirrakhimov Erkin	2020 Nothing to be declared
Mullabayeva Guzal	2020 Financial Declaration Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Servier : Hypertension
Nesukay Elena	2020 Nothing to be declared
Neubeck Lis	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Daiichi Sankyo : Atrial fibrillation - Pfizer : Atrial fibrillation - Novo-Nordisk : CVD diabetes - Servier : Digital health
Nielsen Jens Cosedis	2020 Other Positions of Influence Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Member of Danish Heart Foundation Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - I received institutional research grants from the Novo Nordisk Foundation

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ozdogan Oner	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Recordati International : Alipza - Menarini : Corolan - Astra Zeneca : Crestor - Daiichi Sankyo : Effient - Pfizer : Eliguis - Abbott : Lipanthyl - Daiichi Sankyo : Lixiana - Servier : Triplixam
Pagava Zurab	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Berlin Chemie AG (Georgia) : Spieker fees - Servier (Georgia) : Spieker fees - AstraZeneca (Georgia) : Spieker fees <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Spieker fees

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Patel Riyaz	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Advisory board - Lipid management pathways in primary care</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Amgen : FH pathways</p>
Pavlova Olga	<p>2020</p> <p>Nothing to be declared</p>
Pella Daniel	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Pfizer : speaker fees - Servier : speaker fees - Amgen : speaker fees, advisory board fees - Merck Sharp & Dohme : speaker fees - Novartis : speaker fees, advisory board fees, committee member - Sanofi Aventis : speaker fees, advisory board fees, committee member</p>
Perk Joep	<p>2020</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
Petronio Anna Sonia	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Boston Scientific : TAVI and mitral treatment - Abbott : TMVR</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Medtronic : TAVI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Pfister Otmar	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer AG : advisory board fees - Pfizer : Speaker fees - Astra Zeneca : Speaker fees, advisory board fees - Boehringer-Ingelheim : speaker fees, advisory board fees - Novartis : Speaker fees, advisory board fees - Vifor International : speaker fees, advisory board fees <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular Prevention - Bayer : Cardiovascular Prevention - Boehringer-Ingelheim : Cardiovascular Prevention - Novartis : Heart Failure
Piepoli Massimo Francesco	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Servier : Speaker fee, consultancy - Boehringer Ingelheim : Speaker fee, consultancy <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - CHF Solutions : Aquapheresis Therapy in heart failure

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Pogosova Nana Goar	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bristol Myers Squibb : Stroke</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - National Society of Preventive Cardiology, President</p>
Prescott Eva	<p>2020</p> <p>Nothing to be declared</p>
Rabacal Carlos Alberto	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bial Portela : CV GLOBAL RISK - MSD : CV GLOBAL RISK - Krka Pharma : CV GLOBAL RISK - Pfizer : CV GLOBAL RISK; VACCINATION - Astra Zeneca : HEART FAILURE - Servier : HEART FAILURE; CV GLOBAL RISK - Menarini : HYPERTENSION; CORONARY ARTERY DISEASE - Sanofi Aventis : VACCINATION</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Menarini : PORTUGUESE ATHEROSCLEROSIS CONGRESS</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Rabacal Carlos Alberto	2020 - Vifor International : PORTUGUESE CARDIOLOGY CONGRESS
Ray Kausik K	2020 Financial Declaration Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. <ul style="list-style-type: none"> - Novo Nordisk : Diabetes - Boehringer Ingelheim : Diabetes - Astra Zeneca : Diabetes Antiplatelets - Resverlogix : epigenetics - Abbott : Lipids - Amgen : lipids - Daiichi Sankyo : Lipids - Novartis : Lipids - Lilly : Lipids - Medicines Company : Lipids - Kowa : lipids - Regeneron : Lipids - Esperion : lipids - New Amsterdam : Lipids - ARCTURUS : lipids - Sanofi Aventis : lipids and Diabetes - Pfizer : lipids Hypertension Research funding from healthcare industry under your direct/personal responsibility (to department or institution). <ul style="list-style-type: none"> - Daiichi Sankyo : Lipids

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ray Kausik K	<p>2020</p> <ul style="list-style-type: none"> - Amgen Inc : lipids - Regeneron : lipids <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - EAS, BCS
Regitz-Zagrosek Vera	<p>2020</p> <p>Nothing to be declared</p>
Reiner Zeljko	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Inclisiran - Amgen : PCSK9 inhibitor - Sanofi Aventis : PCSK9 inhibitor - Pfizer : rare diseases
Richter Dimitrios	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : diabetes - Boehringer-Ingelheim : diabetes - Unipharma : hypertension-thrombosis - Amgen : lipids - Servier : LIPIDS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Richter Dimitrios	<p>2020</p> <ul style="list-style-type: none"> - Sanofi Aventis : Lipids - Lilly : Lipids - Winmedica : lipids - Mylan : lipids - LaVIPHARM : lipids - ELPEN : LIPIDS-THROMBOSIS - Bayer Healthcare : Thrombosis - Leo Pharma : THROMBOSIS <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Bayer : THROMBOSIS - Sanofi Aventis : THROMBOSIS
Rudi Victor	<p>2020</p> <p>Nothing to be declared</p>
Ryden Lars	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Advisory Board and lectures - Bayer : Diabetes and cardiovascular disease - Boehringer Ingelheim Pharma GmbH & Co. KG : Diabetes and cardiovascular disease. Expert committee work. - Novo Nordisk : Diabetes and cardiovascular disease. Lectures and expert committee work. - Astrazeneca : Pharma

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ryden Lars	<p>2020</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - ALL AREAS OF CARDIOLOGY - Part owner of the company Propactus Ltd which engages in educational and advisory activities in the health care sector
Shlyakhto Evgeny	<p>2020</p> <p>Nothing to be declared</p>
Siostrzonek Peter	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS, Diabetes - Daiichi Sankyo : anticoagulation - Boehringer-Ingelheim : Anticoagulation, Diabetes, heart failure - Amgen : Lipid therapy - Sanofi Aventis : Lipid therapy <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulation <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulation

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Sitges Marta	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease - Medtronic : Heart Valve Disease <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Atrial Fibrillation - Menarini : Continuous Education on Cardiovascular Diseases - Novartis : Heart Failure - Merck Sharp & Dohme : Hypercholesterolemia <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Speaker and consultant for Abbot.
Skoric Bosko	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Brilique

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Skoric Bosko	<p>2020</p> <ul style="list-style-type: none"> - Biotest : Cytotect - Berlin Chemie AG : edoxaban - Mylan : Physiotens - Teva Pharmaceutical Industries : prasugrel - Bayer AG : Xarelto
Slapikas Rimvydas	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Amgen : dyslipidaemia - Novartis : dyslipidaemia
Solberg Erik Ekker	<p>2020</p> <p>Nothing to be declared</p>
Sousa Uva Miguel	<p>2020</p> <p>Nothing to be declared</p>
Sudano Isabella	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Medtronic : Hypertension - Servier : Hypertension/Lipid - Amgen : Lipid - Daiichi Sankyo : Lipid - Sanofi Aventis : Lipid - Recordati International : Lipid

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Szabados Eszter	<p>2020</p> <p>Nothing to be declared</p>
Tiberi Monica	<p>2020</p> <p>Nothing to be declared</p>
Touyz Rhian	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Novartis : Consultancy-expert opinion
Ungar Andrea	<p>2020</p> <p>Nothing to be declared</p>
Verschuren Monique	<p>2020</p> <p>Nothing to be declared</p>
Viigimaa Margus	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes - Novo-Nordisk : Diabetes - Sanofi Aventis : Diabetes, lipids - Menarini : Hypertension - Amgen : Lipids
Wiklund Olov	<p>2020</p> <p>Nothing to be declared</p>

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Wood David Allan	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Preventive cardiology - Pfizer : Preventive cardiology <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Novartis : Preventive cardiology - Pfizer : Preventive cardiology - Sanofi Aventis : Preventive cardiology - Novo-Nordisk : Preventive cardiology <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - World Heart Federation Board member (Past President) 2019-20
Zafir Barak	<p>2020</p> <p>Nothing to be declared</p>
Zamorano Gomez Jose Luis	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulation - Pfizer : ANTICOagulation - Bayer AG : HEART FAILURE

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<p>2020</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Abbott Laboratories : Valve - Edwards Lifesciences : Valve disease
ZARIF Bassem	<p>2020</p> <p>Nothing to be declared</p>
Zdrojewski Tomasz	<p>2020</p> <p>Nothing to be declared</p>
Zelveian Parounak	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Pfizer : Hypertension & IHD - Egis Pharma : Hypertension & IHD - Recordati International : Hypertension & IHD - Krka Pharma : Hypertension & IHD - Grindex Pharma : Hypertension & IHD

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Neubeck Lis	<p>2020</p> <ul style="list-style-type: none"> - Pfizer : Atrial fibrillation - Novo-Nordisk : CVD diabetes - Servier : Digital health
Nielsen Jens Cosedis	<p>2020</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - Member of Danish Heart Foundation <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - I received institutional research grants from the Novo Nordisk Foundation
Petersen Steffen Erhard	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.) <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.
Prescott Eva	<p>2020</p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Rakischeva Amina	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Bayer : Atrial Fibrillation - Novartis : Heart Failure
Sitges Marta	<p>2020</p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease - Medtronic : Heart Valve Disease <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> - Abbott : Heart Valve Disease - Edwards Lifesciences : Heart Valve Disease <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Atrial Fibrillation - Menarini : Continuous Education on Cardiovascular Diseases - Novartis : Heart Failure - Merck Sharp & Dohme : Hypercholesterolemia

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Sitges Marta	<p>2020</p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. - Speaker and consultant for Abbot.</p>
Touyz Rhian	<p>2020</p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Consultancy-expert opinion</p>